Serotonergic psychedelics, such as psilocybin and LSD, are also commonly referred to as hallucinogens because at higher "trip-inducing" doses (as opposed to microdoses), these drugs typically trigger ...

A new study suggests that the long-term antidepressant effects of psychedelics may be driven by persistent changes in how ...

Suven Life Sciences Ltd. has identified 5-HT1A receptor agonists and 5-HT2A receptor antagonists reported to be useful for the treatment of depression, insomnia, schizophrenia, bipolar and cognitive ...

2A Biosciences Inc. has divulged compounds acting as 5-HT2A and 5-HT2C receptor agonists reported to be useful for the treatment of atopic dermatitis, conjunctivitis, Crohn’s disease, type 2 diabetes, ...

It is becoming increasingly accepted that classic psychedelics like LSD, psilocybin, ayahuasca, and mescaline can act as antidepressants and anti-anxiety treatments in addition to causing ...

Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and neurocognitive disorders, announced the publication of its latest research, Treatment with shRNA to ...

The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Psychedelics activate the 5-HT2A receptor, upregulate brain-derived neurotrophic factor, and enhance synaptic plasticity, leading to therapeutic potential for stress and psychiatric disorders. Credit ...

GM-2505, a novel 5-HT2A receptor agonist and 5-HT releaser, demonstrated rapid, robust, and durable antidepressant effect in MDD NEW YORK, May 27, 2025 /PRNewswire/ -- Gilgamesh Pharmaceuticals, a ...

Receptors mediate the transmission of information between nerve cells. The release of serotonin alters nerve cell activities throughout the brain. At least 14 types of serotonergic receptors can be ...